SCHEMBL5455848

SCHEMBL5455848

NC(=O)c1c(NC(=O)Nc2ccc(F)cc2)sc2c(Cl)c(O)ccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.43
MAPT P10636 4/20 0.43
MEN1 O00255 3/20 0.43
ALDH1A1 P00352 3/20 0.43
GAA P10253 3/20 0.43
KDM4E B2RXH2 2/20 0.43
POLB P06746 1/20 0.43
PPARG P37231 1/20 0.43
NCOA2 Q15596 1/20 0.43
NCOA1 Q15788 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
KCNH2 Q12809 7/20 0.42
CNR1 P21554 1/20 0.42
CA12 O43570 3/20 0.41
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA9 Q16790 3/20 0.41
CA4 P22748 1/20 0.41
CA7 P43166 1/20 0.41
RAB9A P51151 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5455851 0.85 STING1 (0.40) KMT2AMAPTMEN1ALDH1A1GAA
SCHEMBL5458492 0.79 NPC1 (0.48) ALDH1A1KDM4ERAB9ANPC1P2RX1
SCHEMBL5466938 0.78 CA12 (0.44) KMT2AMAPTMEN1ALDH1A1GAA
SCHEMBL5458431 0.77 FLT3 (0.45) KMT2AMEN1ALDH1A1GAARAB9A
SCHEMBL5456366 0.76 FLT3 (0.52) KMT2AMAPTMEN1ALDH1A1KDM4E
SCHEMBL5455834 0.76 MEN1 (0.48) KMT2AMAPTMEN1ALDH1A1GAA
SCHEMBL5466113 0.75 FLT3 (0.42) KMT2AMAPTMEN1ALDH1A1GAA
SCHEMBL5456073 0.75 FLT3 (0.46) KMT2AMAPTMEN1
SCHEMBL17625479 0.75 MEN1 (0.50) KMT2AMAPTMEN1ALDH1A1KDM4E
SCHEMBL5460181 0.74 GRIN2C (0.44) KMT2AMAPTMEN1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 KMT2A 4785/4885MAPT 21/4885MEN1 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.